122. Superficial siderosis Clinical trials / Disease details


Clinical trials : 3 Drugs : 3 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000021218
2024/09/3026/02/2016Evaluation of iron chelator administration, and cochlear implantation for superficial siderosis (ECHACISS)Evaluation of iron chelator administration, and cochlear implantation for superficial siderosis (ECHACISS) - ECHACISS superficial siderosis of CNSdeferiprone administration
cochlear implantation
Department of Neurology, Tokyo Medical and Dental UniversityDepartment of Neurology, Kouchi University HospitalRecruiting20years-oldNot applicableMale and Female5Not applicableJapan
2NCT04890808
(ClinicalTrials.gov)
May 202312/5/2021Therapeutic Antioxidant SupplementationTherapeutic Antioxidant Supplementation for Enhancement of Neural Protection From Free-iron Toxicity in Superficial SiderosisSuperficial SiderosisDietary Supplement: Inosine;Dietary Supplement: IP6Superficial Siderosis Research Alliance Inc.NULLNot yet recruiting16 Years77 YearsAll50N/ANULL
3JPRN-jRCTs031180438
01/04/201927/03/2019Evaluation of iron chelator administration, and cochlear implantation for superficial siderosisEvaluation of iron chelator administration, and cochlear implantation for superficial siderosis - ECHACISS Superficial siderosis
siderosis, cerebellar ataxia, hearing loss, superficial siderosis
1. Administration of Deferiprone orally 30mg/kg after every meal for 36 months.
2. Artificial cochlear implantation for severe hearing disturbance
Sanjo NobuoNULLRecruiting>= 20age oldNot applicableBoth50N/AJapan